GHRP-6 vs Retatrutide
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
GHRP-6
Growth Hormone Releasing Peptide 6 (GHRP-6) is one of the first synthetic growth hormone secretagogues discovered. It stimulates significant GH release but is known for causing intense hunger.
Full details →Retatrutide
Retatrutide is an investigational triple agonist targeting GIP, GLP-1, and glucagon receptors. Phase 2 trials showed unprecedented weight loss of up to 24% at 48 weeks, making it potentially the most effective obesity treatment studied.
Full details →Side-by-Side Comparison
| Aspect | GHRP-6 | Retatrutide |
|---|---|---|
| Mechanism | Acts as a ghrelin mimetic, binding to the GHS-R receptor in the pituitary and hypothalamus. Stimulates GH release and also significantly increases appetite by mimicking ghrelin's hunger-signaling effects. | Triple receptor activation provides complementary metabolic effects: GLP-1 and GIP reduce appetite and improve insulin sensitivity, while glucagon receptor activation increases energy expenditure and promotes hepatic fat oxidation. |
| Typical Dosage | Typical dosing: 100-300mcg administered 2-3 times daily. Often combined with GHRH peptides like CJC-1295 for synergistic effects. | Clinical trials used doses from 1mg to 12mg weekly. Optimal dosing still being determined in ongoing Phase 3 trials. |
| Administration | Subcutaneous injection. Best administered on an empty stomach. The strong hunger response can be beneficial for those trying to gain weight but challenging for cutting. | Subcutaneous injection once weekly. Currently only available through clinical trials - not yet FDA approved. |
| Side Effects | Intense hunger (most notable effect), water retention, increased cortisol and prolactin, tingling/numbness, and potential blood pressure changes. | Similar GI effects to other incretin-based therapies: nausea, diarrhea, vomiting, constipation. Dose-dependent severity. |
| Best For |